469 related articles for article (PubMed ID: 27478331)
1. OTX1 Contributes to Hepatocellular Carcinoma Progression by Regulation of ERK/MAPK Pathway.
Li H; Miao Q; Xu CW; Huang JH; Zhou YF; Wu MJ
J Korean Med Sci; 2016 Aug; 31(8):1215-23. PubMed ID: 27478331
[TBL] [Abstract][Full Text] [Related]
2. Diacylglycerol kinase alpha enhances hepatocellular carcinoma progression by activation of Ras-Raf-MEK-ERK pathway.
Takeishi K; Taketomi A; Shirabe K; Toshima T; Motomura T; Ikegami T; Yoshizumi T; Sakane F; Maehara Y
J Hepatol; 2012 Jul; 57(1):77-83. PubMed ID: 22425622
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of castor zinc finger 1 predicts poor prognosis and facilitates hepatocellular carcinoma progression via MAPK/ERK signaling.
Wang JL; Yang MY; Xiao S; Sun B; Li YM; Yang LY
J Exp Clin Cancer Res; 2018 Mar; 37(1):45. PubMed ID: 29506567
[TBL] [Abstract][Full Text] [Related]
4. Lentivirus-mediated shRNA Targeting CNN2 Inhibits Hepatocarcinoma
Kang X; Wang F; Lan X; Li X; Zheng S; Lv Z; Zhuang Y; Zhao Y; Zhou S
Int J Med Sci; 2018; 15(1):69-76. PubMed ID: 29333089
[No Abstract] [Full Text] [Related]
5. Long non-coding RNA LINC01503 promotes the progression of hepatocellular carcinoma via activating MAPK/ERK pathway.
Wang MR; Fang D; Di MP; Guan JL; Wang G; Liu L; Sheng JQ; Tian DA; Li PY
Int J Med Sci; 2020; 17(9):1224-1234. PubMed ID: 32547318
[No Abstract] [Full Text] [Related]
6. HOXB7 promotes tumor progression via bFGF-induced activation of MAPK/ERK pathway and indicated poor prognosis in hepatocellular carcinoma.
Wang WM; Xu Y; Wang YH; Sun HX; Sun YF; He YF; Zhu QF; Hu B; Zhang X; Xia JL; Qiu SJ; Zhou J; Yang XR; Fan J
Oncotarget; 2017 Jul; 8(29):47121-47135. PubMed ID: 28454092
[TBL] [Abstract][Full Text] [Related]
7. ERK pathway activation contributes to the tumor-promoting effects of hepatic stellate cells in hepatocellular carcinoma.
Xie YX; Liao R; Pan L; Du CY
Immunol Lett; 2017 Aug; 188():116-123. PubMed ID: 28668554
[TBL] [Abstract][Full Text] [Related]
8. TRIM52 up-regulation in hepatocellular carcinoma cells promotes proliferation, migration and invasion through the ubiquitination of PPM1A.
Zhang Y; Tao R; Wu SS; Xu CC; Wang JL; Chen J; Yu YS; Tang ZH; Chen XH; Zang GQ
J Exp Clin Cancer Res; 2018 Jun; 37(1):116. PubMed ID: 29898761
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of chaperonin containing TCP1, subunit 3 predicts poor prognosis in hepatocellular carcinoma.
Cui X; Hu ZP; Li Z; Gao PJ; Zhu JY
World J Gastroenterol; 2015 Jul; 21(28):8588-604. PubMed ID: 26229401
[TBL] [Abstract][Full Text] [Related]
10. Long noncoding RNA MAFG-AS1 facilitates the progression of hepatocellular carcinoma via targeting miR-3196/OTX1 axis.
Hu ZQ; Li HC; Teng F; Chang QM; Wu XB; Feng JF; Zhang ZP
Eur Rev Med Pharmacol Sci; 2020 Dec; 24(23):12131-12143. PubMed ID: 33336731
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of paraoxonase 3 contributes to aggressive human hepatocellular carcinoma progression and associates with poor prognosis.
Jin Y; Li Q; Qiu J; Zhao X; Zheng C; Lv S; Bai Y; Shan Y; Ye LC
Tumour Biol; 2016 Oct; 37(10):14193-14203. PubMed ID: 27553024
[TBL] [Abstract][Full Text] [Related]
12. Ack1 overexpression promotes metastasis and indicates poor prognosis of hepatocellular carcinoma.
Lei X; Li YF; Chen GD; Ou DP; Qiu XX; Zuo CH; Yang LY
Oncotarget; 2015 Dec; 6(38):40622-41. PubMed ID: 26536663
[TBL] [Abstract][Full Text] [Related]
13. ERCC6L promotes the progression of hepatocellular carcinoma through activating PI3K/AKT and NF-κB signaling pathway.
Chen H; Wang H; Yu X; Zhou S; Zhang Y; Wang Z; Huang S; Wang Z
BMC Cancer; 2020 Sep; 20(1):853. PubMed ID: 32891122
[TBL] [Abstract][Full Text] [Related]
14. NMI promotes hepatocellular carcinoma progression via BDKRB2 and MAPK/ERK pathway.
Zhao J; Dong QZ; Zhong F; Cai LL; Qin ZY; Liu Y; Lin CZ; Qin LX; He FC
Oncotarget; 2017 Feb; 8(7):12174-12185. PubMed ID: 28077802
[TBL] [Abstract][Full Text] [Related]
15. The suppressor of cytokine signaling 2 (SOCS2) inhibits tumor metastasis in hepatocellular carcinoma.
Cui M; Sun J; Hou J; Fang T; Wang X; Ge C; Zhao F; Chen T; Xie H; Cui Y; Yao M; Li J; Li H
Tumour Biol; 2016 Oct; 37(10):13521-13531. PubMed ID: 27465557
[TBL] [Abstract][Full Text] [Related]
16. Caveolin-1 overexpression is associated with hepatocellular carcinoma tumourigenesis and metastasis.
Tse EY; Ko FC; Tung EK; Chan LK; Lee TK; Ngan ES; Man K; Wong AS; Ng IO; Yam JW
J Pathol; 2012 Mar; 226(4):645-53. PubMed ID: 22072235
[TBL] [Abstract][Full Text] [Related]
17. ECT2 regulates the Rho/ERK signalling axis to promote early recurrence in human hepatocellular carcinoma.
Chen J; Xia H; Zhang X; Karthik S; Pratap SV; Ooi LL; Hong W; Hui KM
J Hepatol; 2015 Jun; 62(6):1287-95. PubMed ID: 25617497
[TBL] [Abstract][Full Text] [Related]
18. CSIG promotes hepatocellular carcinoma proliferation by activating c-MYC expression.
Cheng Q; Yuan F; Lu F; Zhang B; Chen T; Chen X; Cheng Y; Li N; Ma L; Tong T
Oncotarget; 2015 Mar; 6(7):4733-44. PubMed ID: 25749381
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of PRAME Suppresses Proliferation and Promotes Apoptosis in Hepatocellular Carcinoma Through the Activation of P53 Mediated Pathway.
Zhu H; Wang J; Yin J; Lu B; Yang Q; Wan Y; Jia C
Cell Physiol Biochem; 2018; 45(3):1121-1135. PubMed ID: 29439259
[TBL] [Abstract][Full Text] [Related]
20. SWELL1 promotes cell growth and metastasis of hepatocellular carcinoma in vitro and in vivo.
Lu P; Ding Q; Li X; Ji X; Li L; Fan Y; Xia Y; Tian D; Liu M
EBioMedicine; 2019 Oct; 48():100-116. PubMed ID: 31597595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
